Strategy for retroviral immunotherapy

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 39/00 (2006.01) A61K 39/21 (2006.01) A61K 45/06 (2006.01) A61P 31/18 (2006.01)

Patent

CA 2476956

The present inventor has noted that at least two populations of immune cells are produced in response to retroviruses which infect mammals. More particularly, the immune system of a mammal infected with a retrovirus is capable of mounting an immune response against the virus through a group of cells herein generally referred to as "effector cells", however, a second population of cells are also produced which regulate the "effector cells", herein generally referred to as "regulator cells" (or suppressor cells), limiting the mammal's ability to effectively control or eradicate the retroviral infection. Accordingly, the present invention utilizes these observations to provide methods for treating a mammal with a retroviral infection. Furthermore, the present inventor has found that acute phase inflammatory markers can be used to detect and monitor an"effector cell" response to retroviral antigens.

L'inventeur a noté qu'au moins deux populations de cellules immunes sont produites en réponse aux rétrovirus qui infectent des mammifères. Plus particulièrement, le système immunitaire d'un mammifère infecté par un rétrovirus est capable de mobiliser une réponse immunitaire contre le virus grâce à un groupe de cellules désignées d'une manière générale par le terme "cellules effectrices"; cependant, une deuxième population de cellules est également produite, qui régule les "cellules effectrices" et est désignée d'une manière générale par le terme "cellules régulatrices" (ou de suppression), qui limitent la capacité du mammifère de contrôler efficacement ou d'éradiquer l'infection rétrovirale. De ce fait, la présente invention utilise ces observations pour proposer des procédés de traitement d'un mammifère affecté par une infection rétrovirale. En outre, l'inventeur a découvert que les marqueurs inflammatoires en phase aiguë peuvent s'utiliser pour détecter et surveiller une réponse de cellules effectrices aux antigènes rétroviraux.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Strategy for retroviral immunotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Strategy for retroviral immunotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Strategy for retroviral immunotherapy will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2060247

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.